Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexamethasone krka tafla 4 mg
krka, d.d., novo mesto - dexamethasonum fosfat - tafla - 4 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexamethasone hameln stungulyf, lausn 4 mg/ml
hameln pharma gmbh - dexamethasonum natríumfosfat - stungulyf, lausn - 4 mg/ml
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
kyprolis
amgen europe b.v. - carfilzomib - mergæxli - Æxlishemjandi lyf - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexaject stungulyf, lausn 2 mg/ml
dopharma research b.v.* - dexamethasonum natríumfosfat - stungulyf, lausn - 2 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexametason abcur tafla 1 mg
abcur ab - dexamethasonum fosfat - tafla - 1 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexametason abcur tafla 4 mg
abcur ab - dexamethasonum fosfat - tafla - 4 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexavit stungulyf/innrennslislyf, lausn 4 mg/ml
vital pharma nordic aps - dexamethasonum natríumfosfat - stungulyf/innrennslislyf, lausn - 4 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
maxidex augndropar, dreifa 1 mg/ml
novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
opnol augndropar, lausn 1 mg/ml
karo pharma ab* - dexamethasonum fosfat - augndropar, lausn - 1 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
tobradex augndropar, dreifa
novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa